Browse PAK7

Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles between the nucleus and the mitochondria, and mitochondrial localization is essential for the role in cell survival.
Domain PF00786 P21-Rho-binding domain
PF00069 Protein kinase domain
Function

Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, proliferation or cell survival. Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates the proto-oncogene RAF1 and stimulates its kinase activity. Promotes cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Phosphorylates CTNND1, probably to regulate cytoskeletal organization and cell morphology. Keeps microtubules stable through MARK2 inhibition and destabilizes the F-actin network leading to the disappearance of stress fibers and focal adhesions.

> Gene Ontology
 
Biological Process GO:0007611 learning or memory
GO:0007612 learning
GO:0007613 memory
GO:0007626 locomotory behavior
GO:0016049 cell growth
GO:0044708 single-organism behavior
GO:0050890 cognition
GO:0097191 extrinsic apoptotic signaling pathway
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0005057 receptor signaling protein activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04360 Axon guidance
hsa04510 Focal adhesion
hsa04660 T cell receptor signaling pathway
hsa04810 Regulation of actin cytoskeleton
Reactome -
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PAK7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PAK7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PAK7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4080.637
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4220.761
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4050.78
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0580.885
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0580.925
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0730.816
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PAK7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.311.82.51
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414014.3-14.31
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.54.114.40.0315
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.55.113.40.102
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211742.911.831.10.07
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.516.720.80.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131146.29.137.10.0778
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.214.3-8.10.586
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PAK7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PAK7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PAK7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PAK7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PAK7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PAK7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPAK7
Namep21 protein (Cdc42/Rac)-activated kinase 7
Aliases KIAA1264; p21(CDKN1A)-activated kinase 7; PAK-7; p21-activated kinase 5; p21-activated kinase 7; p21CDKN1A-a ......
Chromosomal Location20p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PAK7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.